Your best source on healthcare and wellness news from Florida

Provided by AGP

Got News to Share?

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on May 22, 2026

Braveminds Academy Earns Top National and Florida Mental Health Honors
Mobility City Welcomes New Franchise Owners to Boca Raton Headquarters for Corporate Training
Mental Health Awareness: Author and Advocate Receives Encouraging Response From Ginuwine
MedTech Co-Founder Presents Novel Breathing Technologies at ATS Respiratory Innovation Summit in Orlando
CMG Containers Expands Refrigerated Containers for Sale for Temperature-Sensitive Storage Needs
Organifi Parasite Cleanse Kit: The Most Effective Herbal Parasite Binding Detox Supplements on the Market
Slim Tide Under Investigation: Critical Research Details Ingredients' Effectiveness for Metabolic & Digestive Support
Calidi Biotherapeutics Provides Required NYSE American Disclosure
GlycoPulse Claims Evaluated: Most Advanced Blood Sugar Support Ingredients for Healthy Glucose Management by Glyco Pulse
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
SCYNEXIS Announces One-for-Eight Reverse Stock Split
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
NANOBIOTIX annonce l’exercice integral de l’option de surallocation, portant le produit de l'offre a 100 millions de dollars
XTL Announces Receipt of Staff Delist Determination from Nasdaq
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

Share us

on your social networks:

Sign up for:

Florida Health Daily

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.